COVID-19 Vaccine
The Centers For Medicare and Medicaid (CMS) Release Billing Guidelines for COVID-19 Vaccine
Medicaid /OHP
Trillium Community Health Plan (Trillium) is closely following advancements in the prevention and treatment of COVID-19, including vaccinations. As a healthcare provider, you will play an integral role as COVID-19 vaccines become available. We want to update you on important new information about vaccine coverage.
To prepare for vaccine administration, the Centers for Medicare and Medicaid (CMS) have published billing guidance (PDF) for Medicaid and Children’s Health Insurance Program (CHIP) providers. Similar to other COVID-19 services, the vaccines will be offered at no cost to your patients. In addition:
- Trillium will configure its systems to properly adjudicate COVID-19 vaccine-related claims, both for the vaccine and its administration, in accordance with Oregon’s coverage determinations for Medicaid beneficiaries
- Member liability will be $0
- Non-participating provider pre-auth requirements will be waived
- Provider reimbursement rates and emergency use authorizations (EUA) are all still pending and we will update you as that information becomes available
The American Medical Association (AMA) has published updates to the Current Procedural Terminology (CPT®) code set that includes new vaccine-specific codes to report immunizations for the novel coronavirus (SARS-CoV-2). The code set will continue to be updated as additional vaccines receive EUA approval by the U.S. Food & Drug Administration (FDA).
The following codes have been published as of November 10, 2020. However, they will not be billable until the specific vaccine receives official EUA approval.
Code |
CPT Short Descriptor |
Labeler Name |
Vaccine/Procedure Name |
---|---|---|---|
91300 |
SARSCOV2 VAC 30MCG/0.3ML IM |
Pfizer |
Pfizer-Biotech Covid-19 Vaccine |
0001A |
ADM SARSCOV2 VAC 30MCG/0.3ML 1ST |
Pfizer |
Pfizer-Biotech Covid-19 Vaccine Administration – First Dose |
0002A |
ADM SARSCOV2 VAC 30MCG/0.3ML 2ND |
Pfizer |
Pfizer-Biotech Covid-19 Vaccine Administration – Second Dose |
91301 |
SARSCOV2 VAC 100MCG/0.5ML IM |
Moderna |
Moderna Covid-19 Vaccine |
0011A |
ADM SARSCOV2 VAC 100MCG/0.5ML 1ST |
Moderna |
Moderna Covid-19 Vaccine Administration – First Dose |
0012A |
ADM SARSCOV2 VAC 100MCG/0.5ML 2ND |
Moderna |
Moderna Covid-19 Vaccine Administration – Second Dose |
Additionally, CMS has also published a set of toolkits to help providers prepare to swiftly administer the vaccine once it is available. If you have any further questions about this upcoming vaccine or the COVID-19 services Trillium covers, please contact Provider Services at 1-877-600-5472 (TTY/TDD: 711).
Medicare Advantage
Trillium Medicare Advantage is closely following advancements in the prevention and treatment of COVID-19, including vaccinations. As a healthcare provider, you will play an integral role as COVID-19 vaccines become available. We want to update you on important new information about vaccine coverage.
To prepare for vaccine administration, the Centers for Medicare and Medicaid (CMS) have published billing guidelines for Medicare providers. Similar to other COVID-19 services, the vaccines will be offered at no cost to your patients. However, please be aware the following billing specifics:
- For Calendar Years (CYs) 2020 and 2021, Medicare payment for the COVID-19 vaccine and its administration for Medicare Advantage plan members will be made through the original fee-for-service Medicare program.
- Trillium Medicare Advantage will not be able to process these claims.
- Therefore, providers must submit claims for administering the COVID-19 vaccine to their CMS Medicare Administrative Contractor (MAC) using product-specific codes for each vaccine approved.
The American Medical Association (AMA) has published updates to the Current Procedural Terminology (CPT®) code set that includes new vaccine-specific codes to report immunizations for the novel coronavirus (SARS-CoV-2). The code set will continue to be updated as additional vaccines receive emergency use authorization (EUA) approval by the U.S. Food & Drug Administration (FDA).
The following codes have been published as of November 10, 2020. However, they will not be billable until the specific vaccine receives official EUA approval.
Code |
CPT Short Descriptor |
Labeler Name |
Vaccine/Procedure Name |
---|---|---|---|
91300 |
SARSCOV2 VAC 30MCG/0.3ML IM |
Pfizer |
Pfizer-Biotech Covid-19 Vaccine |
0001A |
ADM SARSCOV2 VAC 30MCG/0.3ML 1ST |
Pfizer |
Pfizer-Biotech Covid-19 Vaccine Administration – First Dose |
0002A |
ADM SARSCOV2 VAC 30MCG/0.3ML 2ND |
Pfizer |
Pfizer-Biotech Covid-19 Vaccine Administration – Second Dose |
91301 |
SARSCOV2 VAC 100MCG/0.5ML IM |
Moderna |
Moderna Covid-19 Vaccine |
0011A |
ADM SARSCOV2 VAC 100MCG/0.5ML 1ST |
Moderna |
Moderna Covid-19 Vaccine Administration – First Dose |
0012A |
ADM SARSCOV2 VAC 100MCG/0.5ML 2ND |
Moderna |
Moderna Covid-19 Vaccine Administration – Second Dose |
Additionally, CMS has also published a set of toolkits to help providers prepare to swiftly administer the vaccine once it is available. If you have any further questions about this upcoming vaccine or the COVID-19 services Trillium Medicare Advantage covers, please contact Provider Services at 1-844-867-1156; (TTY: 711).